Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Non Operating Income (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Non Operating Income for 17 consecutive years, with $400000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 60.0% to $400000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $800000.0, a 27.27% decrease, with the full-year FY2025 number at $800000.0, down 27.27% from a year prior.
  • Non Operating Income was $400000.0 for Q4 2025 at Myriad Genetics, roughly flat from $400000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $115.1 million in Q3 2021 to a low of -$2.9 million in Q1 2021.
  • A 5-year average of $7.0 million and a median of -$100000.0 in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: skyrocketed 2907.32% in 2021, then crashed 2300.0% in 2023.
  • Myriad Genetics' Non Operating Income stood at -$400000.0 in 2021, then skyrocketed by 300.0% to $800000.0 in 2022, then tumbled by 237.5% to -$1.1 million in 2023, then surged by 190.91% to $1.0 million in 2024, then tumbled by 60.0% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Non Operating Income are $400000.0 (Q4 2025), $400000.0 (Q3 2025), and -$100000.0 (Q2 2025).